Relypsa, Inc. is a United States-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of polymer-based medicines. The Company's technology platform includes a high-throughput chemistry process, enabling the Company to explore various potential polymer medicines for each disease it seeks to address. Its polymers are non-absorbed, meaning they act within the gastrointestinal tract and do not get absorbed into the bloodstream or other parts of the body. Its polymer technology may be able to address many health conditions in need of viable treatment options. Its VELTASSA (patiromer) for oral suspension is a commercialized medicine resulting from its polymer technology platform. VELTASSA is a potassium binder approved for the treatment of hyperkalemia. Available in powder form, VELTASSA is mixed with water and taken daily. VELTASSA's spherical beads bind to potassium in exchange for calcium, primarily in the colon.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:RLYP
- CUSIP: N/A
- Web: www.relypsa.com/
Average Prices:- 50 Day Moving Avg: $30.31
- 200 Day Moving Avg: $20.28
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.13
- P/E Growth: 0.00
Profitability:- Net Margins: -1,601.53%
- Return on Equity: -227.26%
- Return on Assets: -115.06%
Misc:
Frequently Asked Questions for Relypsa (NASDAQ:RLYP)
What is Relypsa's stock symbol?
Relypsa trades on the NASDAQ under the ticker symbol "RLYP."
How were Relypsa's earnings last quarter?
Relypsa Inc (NASDAQ:RLYP) posted its quarterly earnings results on Wednesday, May, 4th. The company reported ($1.26) EPS for the quarter, beating the consensus estimate of ($1.46) by $0.20. The business earned $12.40 million during the quarter, compared to analysts' expectations of $6.88 million. Relypsa had a negative return on equity of 227.26% and a negative net margin of 1,601.53%. During the same period last year, the firm earned ($0.78) EPS. View Relypsa's Earnings History.
Where is Relypsa's stock going? Where will Relypsa's stock price be in 2017?
5 brokers have issued 1 year target prices for Relypsa's shares. Their predictions range from $32.00 to $32.00. On average, they anticipate Relypsa's share price to reach $32.00 in the next twelve months. View Analyst Ratings for Relypsa.
Who are some of Relypsa's key competitors?
Some companies that are related to Relypsa include Amgen (AMGN), Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Exelixis (EXEL), TESARO (TSRO), Bioverativ (BIVV), Kite Pharma (KITE), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), BeiGene (BGNE), GW Pharmaceuticals PLC (GWPH) and Agios Pharmaceuticals (AGIO).
How do I buy Relypsa stock?
Shares of Relypsa can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Relypsa's stock price today?
One share of Relypsa stock can currently be purchased for approximately $31.99.
MarketBeat Community Rating for Relypsa (NASDAQ RLYP)MarketBeat's community ratings are surveys of what our community members think about Relypsa and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Relypsa (NASDAQ:RLYP) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 5 Hold Ratings |
| Consensus Rating: | Hold (Score: 2.00) |
| Consensus Price Target: | $32.00 (0.03% upside) |
Analysts' Ratings History for Relypsa (NASDAQ:RLYP)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/1/2016 | BTIG Research | Downgrade | Buy -> Neutral | | N/A |  |
| 9/1/2016 | Wedbush | Downgrade | Outperform -> Neutral | $32.00 | N/A | |
| 8/22/2016 | Stifel Nicolaus | Downgrade | Buy -> Hold | $32.00 | N/A | |
| 8/13/2016 | Mizuho | Reiterated Rating | Neutral | $32.00 | N/A | |
| 8/8/2016 | Cantor Fitzgerald | Reiterated Rating | Hold | $32.00 | N/A | |
| 7/22/2016 | HC Wainwright | Downgrade | Buy -> Neutral | $32.00 | N/A | |
| 7/21/2016 | Morgan Stanley | Upgrade | Underweight -> Equal Weight | $9.00 -> $32.00 | N/A | |
| 7/21/2016 | Citigroup Inc. | Downgrade | Buy -> Neutral | $25.00 -> $32.00 | N/A | |
| 7/21/2016 | Brean Capital | Downgrade | Buy -> Hold | | N/A | |
| 5/31/2016 | Oppenheimer Holdings, Inc. | Reiterated Rating | Outperform | $36.00 | N/A | |
| 5/29/2016 | Cowen and Company | Reiterated Rating | Buy | | N/A | |
| 4/1/2016 | Raymond James Financial, Inc. | Initiated Coverage | Market Perform | | N/A | |
| 2/25/2016 | Bank of America Corporation | Reiterated Rating | Buy | $32.00 -> $29.00 | N/A | |
| 11/4/2015 | Guggenheim | Initiated Coverage | Buy | $46.00 | N/A | |
| 10/27/2015 | Nomura | Reiterated Rating | Outperform | $75.00 | N/A | |
(Data available from 7/24/2015 forward)
Earnings History for Relypsa (NASDAQ:RLYP)Earnings History by Quarter for Relypsa (NASDAQ RLYP)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/4/2016 | Q1 | ($1.46) | ($1.26) | $6.88 million | $12.40 million | View | Listen | |
| 2/24/2016 | Q415 | ($1.35) | ($1.40) | $7.37 million | $11.96 million | View | Listen | |
| 11/4/2015 | Q3 | ($0.89) | ($1.24) | $6.67 million | $6.50 million | View | N/A | |
| 8/6/2015 | | ($0.95) | ($0.95) | | $0.01 million | View | N/A | |
| 5/7/2015 | | ($0.87) | ($0.78) | | | View | N/A | |
| 3/11/2015 | Q414 | ($0.68) | ($0.80) | | | View | N/A | |
| 11/10/2014 | | ($0.61) | ($0.57) | | | View | N/A | |
| 8/11/2014 | | ($0.57) | ($0.51) | | | View | N/A | |
| 5/7/2014 | | ($0.56) | ($0.54) | | | View | N/A | |
| 3/17/2014 | Q413 | ($0.50) | ($0.68) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Relypsa (NASDAQ:RLYP)2017 EPS Consensus Estimate: ($6.50)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($1.65) | ($1.65) | ($1.65) |
| Q2 2017 | 1 | ($1.64) | ($1.64) | ($1.64) |
| Q3 2017 | 1 | ($1.62) | ($1.62) | ($1.62) |
| Q4 2017 | 1 | ($1.59) | ($1.59) | ($1.59) |
(Data provided by Zacks Investment Research)
Dividend History for Relypsa (NASDAQ:RLYP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Relypsa (NASDAQ:RLYP)Insider Trades by Quarter for Relypsa (NASDAQ:RLYP)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/17/2016 | James D Dondero | Major Shareholder | Buy | 500 | $31.92 | $15,960.00 | |
| 8/16/2016 | Monte Montgomery | Insider | Sell | 510 | $31.92 | $16,279.20 | |
| 8/11/2016 | James D Dondero | Major Shareholder | Sell | 37,000 | $31.96 | $1,182,520.00 | |
| 7/25/2016 | Orbimed Advisors Llc | Major Shareholder | Sell | 4,043,600 | $32.00 | $129,395,200.00 | |
| 6/7/2016 | David W J Mcgirr | Director | Sell | 1,013 | $19.34 | $19,591.42 | |
| 3/16/2016 | Kristine M Ball | CFO | Buy | 7,000 | $12.15 | $85,050.00 | |
| 3/15/2016 | Thomas J Schuetz | Director | Buy | 30,000 | $13.39 | $401,700.00 | |
| 12/31/2015 | Wilhelm Stahl | SVP | Sell | 20,000 | $28.53 | $570,600.00 | |
| 12/23/2015 | Orbimed Advisors Llc | Major Shareholder | Sell | 500,000 | $27.18 | $13,590,000.00 | |
| 12/9/2015 | Lance Berman | SVP | Sell | 750 | $29.50 | $22,125.00 | |
| 12/7/2015 | John A. Orwin | CEO | Sell | 15,000 | $28.28 | $424,200.00 | |
| 12/7/2015 | Lance Berman | SVP | Sell | 30,000 | $29.78 | $893,400.00 | |
| 12/4/2015 | John A. Orwin | CEO | Sell | 40,000 | $25.00 | $1,000,000.00 | |
| 10/22/2015 | Orbimed Advisors Llc | Major Shareholder | Buy | 500,000 | $12.56 | $6,280,000.00 | |
| 8/17/2015 | John A Orwin | CEO | Sell | 5,000 | $24.84 | $124,200.00 | |
| 8/17/2015 | Lance Berman | SVP | Sell | 710 | $24.77 | $17,586.70 | |
| 8/17/2015 | Ronald A Krasnow | Insider | Sell | 522 | $24.75 | $12,919.50 | |
| 6/11/2015 | Thomas J Schuetz | Director | Sell | 1,000 | $34.57 | $34,570.00 | |
| 6/1/2015 | John A Orwin | CEO | Sell | 33,555 | $36.42 | $1,222,073.10 | |
| 5/18/2015 | Orbimed Advisors Llc | Major Shareholder | Sell | 1,457,551 | $34.13 | $49,746,215.63 | |
| 5/11/2015 | Klaus R Dr Veitinger | Director | Sell | 5,834 | $36.06 | $210,374.04 | |
| 4/10/2015 | Klaus R Dr Veitinger | Director | Sell | 5,832 | $35.35 | $206,161.20 | |
| 3/5/2015 | Kristine M Ball | CFO | Sell | 3,519 | $40.68 | $143,152.92 | |
| 2/27/2015 | Ronald A Krasnow | Insider | Sell | 10,348 | $39.00 | $403,572.00 | |
| 2/24/2015 | Lance Berman | SVP | Sell | 5,000 | $38.19 | $190,950.00 | |
| 2/24/2015 | Ronald A Krasnow | Insider | Sell | 10,000 | $39.00 | $390,000.00 | |
| 2/10/2015 | Klaus R Dr Veitinger | Director | Sell | 5,834 | $32.12 | $187,388.08 | |
| 1/21/2015 | Claire Lockey | Insider | Sell | 5,000 | $35.00 | $175,000.00 | |
| 1/21/2015 | Kristine M Ball | CFO | Sell | 3,000 | $36.00 | $108,000.00 | |
| 1/14/2015 | Ronald A Krasnow | Insider | Sell | 5,000 | $33.58 | $167,900.00 | |
| 1/12/2015 | Klaus R Dr Veitinger | Director | Sell | 5,834 | $32.33 | $188,613.22 | |
| 12/12/2014 | Klaus R Dr Veitinger | Director | Sell | 14,169 | $32.16 | $455,675.04 | |
| 12/9/2014 | 5Am Partners Iii, Llc | Major Shareholder | Sell | 589,637 | $30.04 | $17,712,695.48 | |
| 12/9/2014 | Claire Lockey | Insider | Sell | 8,000 | $30.00 | $240,000.00 | |
| 11/25/2014 | Lance Berman | SVP | Sell | 30,000 | $25.00 | $750,000.00 | |
| 10/10/2014 | Klaus R Dr Veitinger | Director | Sell | 2,500 | $19.34 | $48,350.00 | |
| 9/24/2014 | Lance Berman | SVP | Sell | 5,000 | $22.00 | $110,000.00 | |
| 9/17/2014 | Orbimed Advisors Llc | Major Shareholder | Sell | 94,000 | $25.27 | $2,375,380.00 | |
| 9/16/2014 | 5Am Partners Ii, Llc | Major Shareholder | Sell | 612,540 | $26.03 | $15,944,416.20 | |
| 9/10/2014 | Klaus R Dr Veitinger | Director | Sell | 4,167 | $23.00 | $95,841.00 | |
| 8/29/2014 | Wilhelm Stahl | SVP | Sell | 15,785 | $25.29 | $399,202.65 | |
| 8/26/2014 | 5Am Partners Ii, Llc | Major Shareholder | Sell | 433,000 | $26.51 | $11,478,830.00 | |
| 8/25/2014 | Lance Berman | SVP | Sell | 20,000 | $25.89 | $517,800.00 | |
| 8/11/2014 | Klaus R Dr Veitinger | Director | Sell | 4,167 | $27.73 | $115,550.91 | |
| 7/24/2014 | Lance Berman | SVP | Sell | 45,000 | $23.92 | $1,076,400.00 | |
| 7/10/2014 | Klaus R Dr Veitinger | Director | Sell | 4,167 | $23.12 | $96,341.04 | |
| 11/20/2013 | 5Am Partners Iii, Llc | Major Shareholder | Buy | 372,692 | $11.00 | $4,099,612.00 | |
| 11/20/2013 | John A Orwin | CEO | Buy | 15,000 | $11.00 | $165,000.00 | |
| 11/20/2013 | Leaf Ventures I L.P. New | Insider | Buy | 185,978 | $11.00 | $2,045,758.00 | |
| 11/20/2013 | Scott M Rocklage | Director | Buy | 363,328 | $11.00 | $3,996,608.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Relypsa (NASDAQ:RLYP)
Latest Headlines for Relypsa (NASDAQ:RLYP)
| Source: |
|
Relypsa (RLYP) Chart for Monday, July, 24, 2017
